BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38105756)

  • 1. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
    Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
    Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
    Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
    Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
    Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
    Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
    Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
    J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
    Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
    Wang X; Zhao W; Zhang W; Wu S; Yan Z
    J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.
    Zhang LZ; Yang JG; Xia HF; Huang J; Liu HM; Wu M; Liu B; Wang WM; Chen G
    J Dent Res; 2023 Jul; 102(7):795-805. PubMed ID: 37246810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
    Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
    J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA hsa_circ_0055538 regulates the malignant biological behavior of oral squamous cell carcinoma through the p53/Bcl-2/caspase signaling pathway.
    Su W; Sun S; Wang F; Shen Y; Yang H
    J Transl Med; 2019 Mar; 17(1):76. PubMed ID: 30857544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
    Sasabe E; Tomomura A; Yamamoto T
    J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
    Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
    Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
    Cui B; Chen J; Luo M; Liu Y; Chen H; Lü D; Wang L; Kang Y; Feng Y; Huang L; Zhang P
    Int J Oral Sci; 2021 Mar; 13(1):8. PubMed ID: 33692335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
    Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
    Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS.
    Li D; Kou Y; Gao Y; Liu S; Yang P; Hasegawa T; Su R; Guo J; Li M
    Aging (Albany NY); 2021 Jan; 13(3):4242-4257. PubMed ID: 33495407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-191 regulates oral squamous cell carcinoma cells growth by targeting PLCD1 via the Wnt/β-catenin signaling pathway.
    Wang Z; Guan W; Ma Y; Zhou X; Song G; Wei J; Wang C
    BMC Cancer; 2023 Jul; 23(1):668. PubMed ID: 37460940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 17. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
    Ding L; Chen X; Xu X; Qian Y; Liang G; Yao F; Yao Z; Wu H; Zhang J; He Q; Yang B
    Cancer Immunol Res; 2019 Jan; 7(1):136-149. PubMed ID: 30401677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers.
    Xiao D; Zeng T; Zhu W; Yu ZZ; Huang W; Yi H; Lu SS; Feng J; Feng XP; Wu D; Wen Q; Zhou JH; Yuan L; Zhuang W; Xiao ZQ
    Cancer Immunol Res; 2023 Oct; 11(10):1367-1383. PubMed ID: 37566399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.